Page 6 - Sosei Heptares News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaSosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK,

United kingdomCity ofSoult ukpyolsiSouth koreaNew yorkUnited statesRheinland pfalzSosei heptaresErica hollingsworthKentaro taharaFrazer hallSosei heptareLinda ruckelReinhard malinShinichiro nishishitaMaya bennison